Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling

Journal of Clinical Investigation

Volumn 97, Issue 3, 1996, Pages 806-813

  Avis, Ingalill M ^a   Jett, Marti ^b   Boyle, Thomas ^b   Vos, Michele D ^a   Moody, Terry ^a   Treston, Anthony M ^a   Martínez, Alfredo ^a   Mulshine, James L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

5 HETE; apoptosis; growth inhibition; lipoxygenase pathway; signal transduction

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; 15 HYDROXYICOSATETRAENOIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 5 HYDROXYICOSATETRAENOIC ACID; ACETYLSALICYLIC ACID; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; DOCEBENONE; GROWTH FACTOR; LEUKOTRIENE B4; LEUKOTRIENE C4; LEUKOTRIENE E4; LIPOXYGENASE INHIBITOR; NORDIHYDROGUAIARETIC ACID; PROSTAGLANDIN F1 ALPHA; PROSTAGLANDIN F2 ALPHA; SOMATOMEDIN C;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARACHIDONIC ACID METABOLISM; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; LUNG CANCER; MOUSE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030023776     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118480     Document Type: Article

References (39)

1. Garfinkel, E., and E. Silverberg. 1990. Lung cancer and smoking trends in the United States over the past 25 years. Ann. NY Acad. Sci. 609:146-154.
2. Shaw, G., and J Mulshine. 1993 Monoclonal antibodies for early cytologic detection of lung cancer. Seminars in Thoracic and Cardiovascular Surgery 5:201-209.
3. Cuttitta, F , D. Carney, J Mulshine, T. Moody, J. Fedorko, A. Fiscler, and J. Minna. 1985. Bombesin-like peptides can function as autocrine growth factors in human small cell lung cancer. Nature (Lond). 16:823-826.
4. Froesch, E., C. Schmid, J. Schwander, and J Zapf. 1985. Actions of insulin-like growth factors. Ann. Rev. Physiol. 47:443-467
5. Nakanishi, Y., J. Mulshine, P. Kasprzyk, R. Natale, R Maneckjee, I. Avis, A. Treston, A. Gazdar, J. Minna, and F Cuttitta. 1988. Insulin-like growth factor-1 can stimulate the proliferation of human small cell lung cancer lines J Clin. Invest. 82.354-359.
6. Siegfried, J., Y.-H. Han, M. DeMichele, J. Hunt, A. Gaither, and F. Cuttitta 1994 Production of gastrin-releasing peptide by a non-small cell lung carcinoma cell line adapted to serum-free conditions J. Biol Chem. 269:8596-8603.
7. Mulshine, J., A. Treston, F. Scott, I. Avis, C Boland, R. Phelps, P. Kasprzyk, Y. Nakanishi, and F Cuttitta. 1992. Lung cancer: rational strategies for early detection and intervention. Oncology. 5:25-32.
8. Sporn, M., and G. Todaro. 1980. Autocrine secretion and malignant transformation. N. Engl. J. Med. 303:878-880
9. Trepel, J., J Moyer, F Cuttitta, H. Frucht, D. Coy, R. Natale, J Mulshine, R. Jensen, and E. Sausville. 1988. A novel bombesin receptor antagonist inhibits autocrine signals in a small cell lung carcinoma cell line. Biochem. Biophys. Res Commun 156:1383-1389
10. Berridge, M., and R. Irvine. 1989. Inositol phosphates and cell signaling. Nature (Lond). 341:197-205
11. Millar, J., and E. Rozengurt. 1990. Arachidonic acid release by bombesin. J. Biol Chem. 265:19973-19979.
12. Sethi, T , S. Langdon, J Smyth, and E. Rozengurt. 1992. Growth of small cell lung cancer cells: stimulation by multiple neuropeptides and inhibition by broad spectrum antagonists in vitro and in vivo. Cancer Res. 52(Suppl.): 2737s-2742s.
13. Bunn, P.J., D. Dienhart, D. Chan, M. Tagawa, and P Jewett. 1992. Effects of neuropeptides on human lung and breast cancer cells. J. Natl. Cancer Inst. Monogr. 13:145-151.
14. Axelrod, J., R Burch, and C Jelsema 1988. Receptor-mediated activation of phospholipase A2 via GTP-binding proteins: arachidonic acid and its metabolites as second messengers Trends Neurosci 11:117-123.
15. Boyle, T., V. Lancaster, R Hunt, P. Gemski, and M. Jett. 1994. Method for simultaneous quantitation of platelet activating factor and multiple arachidonate metabolites from small samples: analysis of effects of Staphylococcus aureus enterotoxin B in mice. Anal Biochem. 216:373-382.
16. Giovannucci, E , K Egan, D. Hunter, M. Stampfer, G. Golditz, W. Willett, and F. Speizer. 1995. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med. 333:609-614.
17. Henderson, W. 1994. The role of leukotrienes in inflammation. Ann. Intern Med. 121:684-697.
18. Batt, D. 1992. 5-lipoxygenase inhibitors and their anti-inflammatory activities. Prog. Med. Chem. 29.1-63.
19. Larsen, J., and E. Acosta. 1993. Leukotrine-receptor antagonists and 5-lipoxygenase inhibitors in asthma. Ann Pharmacother. 27:898-903.
20. Baserga, R. 1994. Oncogenes and the strategy of growth factors. Cell 79:927-930.
21. Beaven, M., J. Moore, O. Smith, T. Hesketh, and J. Metcalfe. 1984. The calcium signal and phosphatidylinositol breakdown in 2H3 cells. J. Biol. Chem. 259:7137-7142.
22. Gillard J., A. Ford-Hutchinson, C. Chan, S. Charteson, D. Denis, A. Foster, R Fortin, S. Leger, C McFarlane, H. Morton, et al. 1989. L-663.536(MK-886) (3-[-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropaoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Can. J. Physiol. Pharmacol. 67:456-464.
23. Nakanishi, Y., F. Cuttitta, P. Kasprzyk, I. Avis, S. Steinberg, A. Gazdar, and J Mulshine. 1988. Growth factor effects on small cell lung cancer using a colorimetric assay: can a transferrin-like growth factor mediate autocrine growth? Exp. Cell Biol. 56:74-85.
24. Davis, L., M. Dibner, and J. Battey. 1986. Basic Methods in Molecular Biology. Appleton and Lange, East Norwalk, CT. 62-65.
25. Martinez, A., M.-J. Miller, K. Quinn, E. Unsworth, M. Ebina, and F. Cuttitta. 1995. Non-radioactive localization of nucleic acids by direct in situ RT-PCR in paraffin-embedded sections. J. Histochem. Cytochem. 43:739-747.
26. Furukawa, M., T. Yoshimoto, K. Ochi, and S. Yamamoto. 1984. Studies on arachidonate 5-lipoxygenase of rat basophilic leukemia cells. Biochim. Biophys Acta. 795:458-465.
27. Ondrey, F., J. Harris, and K. Anderson. 1989. Inhibition of U937 eicosanoid and DNA synthesis by 5,8,11,14-eicosatetraynoic acid, an inhibitor of arachidonic acid metabolism and its partial reversal by leukotriene C4. Cancer Res. 49:1138-1142.
28. Yamamoto, S., and R Kato. 1992. Inhibitors of the arachidonic acid cascade and their chemoprevention of skin cancer. In Cancer Chemoprevention. L. Wattenberg, M. Lipkin, C. Boone, and G. Kelloff, editors. CRC Press Inc. Boca Rotan, FL. 141-151.
29. Rouzer, C., A. Ford-Hutchinson, H. Morton, and J Gillard. 1990. MK886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes. J. Biol Chem. 265:1436-1442.
30. Piazza, G , A. Rahm, M. Krutzsch, G. Sperl, N. Paranka, P Gross, K. Brendel, R. Burt, D. Alberts, R. Pamukcu, and D. Ahnen. 1995. Antineoplastic drugs Sulindac Sulfide and Sulfone inhibit cell growth by inducing apoptosis. Cancer Res 55:3110-3116
31. Anderson, K., T. Seed, F. Ondrey, and J. Harris. 1994. The selective 5-lipoxygenase inhibitor A63162 reduces PC3 proliferation and initiates morphologic changes consistent with secretion. Anticancer Res. 14:1951-1960.
32. Tsukada, T., K. Nakashima, and S. Shirakawa. 1986. Arachidonic 5-lipoxygenase inhibitors show potent antiproliferative effects on human leukemic cell lines. Biochem Biophys. Res Commun 140:812-816.
33. Leikauf, G., H.-E. Claesson, C. Doupnik, S. Hybbinette, and R. Grafstrom. 1990. Cysteinyl leukotrienes enhance growth of human airway epithelial cells. Am. J. Physiol. 259:L255-L261.
34. Shaw, G., A. Gazdar, R. Phelps, R. Linnoila, D Ihde, B. Johnson, H Oie, H. Pass, S. Steinberg, B. Gosh, et al. 1993. Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing Cancer Res. 53: 5181-5187.
35. Tagari, P., C Brideau, C. Chan, R Frenette, and C. Black. 1993. Assessment of the in vivo biochemical efficacy of orally active leukotrine biosynthesis inhibitors. Agents Actions 40:62-71.
36. Thun, M., M. Nambodin, and C. H. Heath Jr 1991. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 325:1593-1596.
37. Giovannucci, E., E. Rimm, M. Stampler, G. Colditz, A. Ascherio, and W. Willett 1994. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann. Intern. Med 121:241-246.
38. Thompson, C. 1995. Apoptosis in the pathogenesis and treatment of disease. Science (Wash DC). 267:1456-1462.
39. Bedi, A., P. Pasricha, A. Akhtar, J. Barber, G. Bedi, F Giardiello, B. Zehnbauer, S. Hamilton, and R. Jones. 1995. Inhibition of apoptosis during development of colorectal cancer Cancer Res. 55:1811-1816.